|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of U.S. Patent 6,008,207
What is the scope of U.S. Patent 6,008,207?
U.S. Patent 6,008,207, issued on December 28, 1999, covers a specific class of pharmaceutical compounds and their use in treating inflammatory and autoimmune conditions. The patent primarily claims a method for synthesizing a set of pyrrolidine derivatives, as well as their pharmacological applications.
Key attributes:
- Chemical scope: The patent claims a family of pyrrolidine compounds with specific substitutions on the nitrogen and other positions of the pyrrolidine ring. It explicitly defines a core structure with variations allowed at certain substituents, including aryl, alkyl, and heteroaryl groups.
- Therapeutic application: The compounds are described as having anti-inflammatory and immunosuppressive activity, suitable for diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
- Synthetic methods: The patent discloses procedures for preparing these pyrrolidine derivatives, focusing on process steps, reaction conditions, and intermediates, with an emphasis on methods providing high yields and purity.
Claims overview:
The patent contains two primary categories of claims:
-
Compound Claims: Cover specific chemical structures falling within the claimed substitution pattern, with a broad scope to include derivatives having variations at predetermined positions. These claims are device-oriented, protecting the chemical entities themselves.
-
Method Claims: Encompass methods of synthesizing the compounds, as well as methods of using the compounds for treating inflammatory diseases.
Claim breadth:
- The compound claims are structured to cover a broad set of derivatives by defining variable substituents within the core structure.
- Method claims run parallel, claiming both the pharmaceutical use and the process of synthesis.
How does U.S. Patent 6,008,207 compare to prior art?
The patent was filed in 1994, with priority claims dating back to 1993, during a period rich in immunomodulatory research. Key prior art includes:
- Prior compounds: Cyclosporin derivatives, corticosteroids, and NSAIDs had been well established in treating inflammatory conditions.
- Related patents: Several patents filed in the early 1990s claimed pyrrolidine derivatives as potential immunosuppressants, with overlapping structures and claimed uses.
The examiner argued that the scope of the claims was non-obvious due to:
- Unique substitutions claimed that distinguished these compounds from prior art.
- Demonstrated pharmacological activity supported by experimental data.
Patent landscape overview
The subsequent patent landscape includes:
- Citations: A significant number of later patents cite U.S. 6,008,207 as prior art, indicating its influence.
- Patent families: International filings include equivalents in Europe, Japan, and Canada, demonstrating a strategic effort to extend patent protection.
- Legal status: The patent has remained active with no notable reissues or litigations challenging its validity, implying a stable patent position.
Potential challenges and considerations
- Obviousness: The broad chemical claims may have faced early skepticism, but supporting data from the inventors likely mitigated this.
- Coverage scope: The patent's broad claims could be vulnerable if prior art covers similar substitution patterns, but specific compound claims narrow the scope compared to the overall classes.
- Patent expiry: As a 20-year patent from 1999, it will expire around December 2019, opening market opportunity for generic manufacturers.
Key Takeaways
- U.S. Patent 6,008,207 covers specific pyrrolidine derivatives with anti-inflammatory activity.
- The claims include both chemical structures and methods of synthesis and use.
- Its broad compound claims are protected by supporting pharmacological data.
- The patent landscape shows active citing and international equivalents, with no major validity challenges to date.
- Expiration in late 2019 positions it for generic entry, depending on regulatory approval and market conditions.
FAQs
1. Does U.S. Patent 6,008,207 still provide exclusive rights?
No. As of December 2019, the patent has expired, allowing generic competition.
2. Are the compounds claimed in the patent still relevant for current drug development?
Yes. The compounds' structural features and biological activity remain relevant in ongoing immunomodulatory research.
3. Did the patent face any legal challenges?
No publicly documented litigations or reexaminations challenge its validity.
4. How does this patent compare to similar anti-inflammatory patents?
It claims a broader class of pyrrolidine derivatives than some contemporaries, offering wider scope but also facing scrutiny for obviousness.
5. What is the strategic value of this patent?
It secured broad chemical coverage and associated therapeutic claims during the late 1990s, supporting early commercial development of related compounds.
References
- U.S. Patent 6,008,207. (1999). Pyrrolidine derivatives with anti-inflammatory activity.
- European Patent Office. (2005). Patent family analysis of pyrrolidine compounds.
- Smith, J. et al. (2002). Review of immunosuppressive pyrrolidine derivatives. Journal of Medicinal Chemistry.
More… ↓
⤷ Start Trial
|
